Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder (URIS-1)

10. november 2026 oppdatert av: Zuzana Jirásková, General University Hospital, Prague

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder: A Prospective, Randomized, Sham-Controlled Clinical Trial

This prospective, randomized, sham-controlled clinical investigation evaluates the efficacy and safety of peroneal transcutaneous electrical neuromodulation (URIS I system) in children aged 7-12 years with wet overactive bladder and daytime urinary incontinence who did not respond or responded insufficiently to standard urotherapy. Participants are randomized 1:1 to active or sham stimulation and receive 12 weekly bilateral sessions of 30 minutes over 12 weeks.

Studieoversikt

Detaljert beskrivelse

Investigator-initiated academic study sponsored by the General University Hospital in Prague. The primary objective is to determine the effect of peroneal transcutaneous electrical neuromodulation on the frequency of daytime urinary incontinence in children with overactive bladder. The primary variable is the clinical responder rate at the end of treatment (week 12). Secondary objectives are the effect on micturition frequency, functional bladder capacity, parent- and child-reported symptoms and quality of life (DVISS, PIN-Q, PGI-I), clinician-rated global improvement (CGI-I), and the safety, tolerability and adherence to treatment.

Children are randomized 1:1 (permuted blocks, sealed opaque envelopes) to active stimulation or sham stimulation with the stimulation voltage set to 0 V. Both procedures are identical in preparation, electrode placement, duration and the 4 Hz acoustic signal; the child and the parent are separated from the lower limbs by an opaque screen. Planned sample size: 21 evaluable participants per arm; 47 participants are to be enrolled to allow for approximately 10% attrition.

The URIS I device is supplied by the manufacturer, Stimvia s.r.o., under a loan agreement. The manufacturer is not a sponsor or collaborator of this study.

Studietype

Intervensjonell

Registrering (Antatt)

47

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Prague, Tsjekkia, 128 08
        • Rekruttering
        • General University Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

7 år til 12 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Children aged 7 to 12 years, boys and girls
  • Wet form of overactive bladder (urgency with daytime urinary incontinence, with or without nocturnal enuresis)
  • At least 8 wet days during waking hours in 2 weeks, based on the wetting diary
  • No or insufficient response to standard urotherapy (ICCS) lasting at least 3 months
  • Ability and willingness of the child and the parent to follow the protocol; signed informed consent

Exclusion Criteria:

  • Severe daytime incontinence (complete wetting in more than 50% of episodes)
  • Anticholinergic treatment for overactive bladder in the last 3 months
  • Neurogenic lower urinary tract dysfunction
  • Congenital malformations of the lower urinary tract (e.g. bladder exstrophy, anorectal malformation)
  • Severe systemic or neurological disease (e.g. cardiac disorders, epilepsy)
  • Local lesions of the lower limbs (skin disease, osteosynthesis material)
  • Peripheral neuropathy of the lower limbs
  • Presence of an electronic implant in the body (e.g., a neurostimulator)
  • Functional constipation during the previous 3 months (Rome III-IV criteria)
  • Symptomatic urinary tract infection

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Active stimulation

Active bilateral peroneal transcutaneous neuromodulation with URIS I, 30 minutes, once a week for 12 weeks.

Bilateral peroneal transcutaneous electrical neuromodulation with the URIS I system. A neutral self-adhesive electrode is placed on the lower abdomen; the optimal stimulation point at the lateral edge of the popliteal fossa is identified by a rhythmic motor response of the leg, and the stimulation voltage is set to the lowest value that evokes this response. Stimulation lasts 30 minutes, once a week for 12 weeks (12 sessions). The device emits a 4 Hz acoustic signal.

Sham-komparator: Sham stimulation

Sham stimulation with URIS I at 0 V (no stimulation delivered), same procedure, electrode placement, 4 Hz acoustic signal and schedule as the active arm: 30 minutes, once a week for 12 weeks.

Identical preparation, electrode placement and duration as active stimulation, but the stimulation voltage is set to 0 V bilaterally so that no stimulation is delivered. Exposure to active stimulation is limited to the minimum needed to locate the stimulation point. 30 minutes, once a week for 12 weeks (12 sessions). The device emits the same 4 Hz acoustic signal.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of clinical responders at the end of treatment
Tidsramme: Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)

A clinical responder is a child who meets either or both of the following criteria at the end of treatment:

  1. a reduction of at least 50% in the number of wet days during waking hours over 14 days of the wetting diary compared with baseline;
  2. a PGI-I score of 2 or less rated by both the parent and the child. PGI-I (Patient Global Impression of Improvement) ranges from 1 = very much better to 7 = very much worse.
Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in the number of daytime incontinence episodes per 24 hours
Tidsramme: Baseline, Week 6, Week 12

Number of incontinence episodes during waking hours per 24 hours, averaged over 14 days of the wetting diary; change from baseline.

Baseline, Week 6, Week 12
Change in the severity of daytime incontinence episodes
Tidsramme: Baseline, Week 6, Week 12

Severity of incontinence episodes (complete vs. partial wetting) per 24 hours during waking hours over 14 days of the wetting diary; change from baseline.

Baseline, Week 6, Week 12
Change in the number of wet days
Tidsramme: Baseline, Week 6, Week 12

Number of wet days during waking hours over 2 weeks (a wet day is a day with leakage producing a stain on underwear larger than a 10 CZK coin / 1 EUR coin); change from baseline.

Baseline, Week 6, Week 12
Change in micturition frequency and functional bladder capacity
Tidsramme: Baseline, Week 6, Week 12

Mean number of voids per 24 hours and mean voided volume (functional bladder capacity) from the 48-hour frequency-volume chart; change from baseline.

Baseline, Week 6, Week 12
Change in DVISS total score (parent-rated)
Tidsramme: Baseline, Week 6, Week 12

Dysfunctional Voiding and Incontinence Symptom Score total score completed by the parent; change from baseline. Higher scores indicate more severe symptoms.

Baseline, Week 6, Week 12
Change in Bower PIN-Q total score (child-rated)
Tidsramme: Baseline, Week 6, Week 12

Pediatric Incontinence Questionnaire (PIN-Q) total score completed by the child as a measure of quality of life; change from baseline.

Baseline, Week 6, Week 12
PGI-I score rated by the child and by the parent
Tidsramme: Week 6, Week 12

Patient Global Impression of Improvement, rated separately by the child and by the parent (1 = very much better to 7 = very much worse).

Week 6, Week 12
CGI-I score rated by the unblinded investigator
Tidsramme: Week 6, Week 12

Clinical Global Impression of Improvement rated by the principal investigator or co-investigator (1 = very much improved to 7 = very much worse).

Week 6, Week 12
Number, type and severity of treatment-related adverse events
Tidsramme: From the first stimulation to Week 12

Adverse events (description, severity, onset, resolution, action taken and relationship to neuromodulation) recorded at every stimulation session and visit.

From the first stimulation to Week 12
Adherence to treatment
Tidsramme: Week 12

Proportion of participants who attend at least 80% of the 12 planned stimulation sessions.

Week 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Zuzana Jiraskova, MD, FEAPU, General University Hospital, Prague

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. september 2026

Primær fullføring (Antatt)

1. juni 2028

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

10. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • Uris_01_2026
  • 000058 (Annen identifikator: ISZP)
  • sukls114680/2026 (Annen identifikator: State Institute for Drug Control (SUKL))
  • sukl222573/2026 (Annen identifikator: State Institute for Drug Control (SUKL))
  • 376/26 A, IB, D, PS (Annen identifikator: Ethics Committee, General University Hospital in Prague)
  • 443/26 A, IB (Annen identifikator: Ethics Committee, General University Hospital in Prague)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared to protect patient privacy, as this study evaluates a vulnerable pediatric population and is subject to strict GDPR and institutional data protection regulations.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere